These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 30772178

  • 61. Single Low Dose of rFVIIa Combined with Antifibrinolytic Agent is a Simple and Safe Treatment for Factor XI-Deficient Patients undergoing Surgery.
    Salomon O, Budnik I, Avishai E, Tamarin I, Bashari D, Dardik R, Livnat T.
    Thromb Haemost; 2019 Dec; 119(12):1927-1932. PubMed ID: 31493780
    [Abstract] [Full Text] [Related]

  • 62. Recombinant activated factor VII in patients with acute liver failure with UNOS Status 1A: a single tertiary academic centre experience.
    Pham HP, Hsu SX, Parker-Jones S, Samstein B, Diuguid D, Schwartz J.
    Vox Sang; 2014 Jan; 106(1):75-82. PubMed ID: 23815226
    [Abstract] [Full Text] [Related]

  • 63. Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery.
    Al Douri M, Shafi T, Al Khudairi D, Al Bokhari E, Black L, Akinwale N, Osman Musa M, Al Homaidhi A, Al Fagih M, Borum Andreasen R.
    Blood Coagul Fibrinolysis; 2000 Apr; 11 Suppl 1():S121-7. PubMed ID: 10850577
    [Abstract] [Full Text] [Related]

  • 64. Safe use of recombinant activated factor VIIa for recalcitrant postoperative haemorrhage in cardiac surgery.
    Tatoulis J, Theodore S, Meswani M, Wynne R, Hon-Yap C, Powar N.
    Interact Cardiovasc Thorac Surg; 2009 Sep; 9(3):459-62. PubMed ID: 19542087
    [Abstract] [Full Text] [Related]

  • 65.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 66. Thrombotic risk of recombinant factor seven in pediatric cardiac surgery: a single institution experience.
    Karsies TJ, Nicol KK, Galantowicz ME, Stephens JA, Kerlin BA.
    Ann Thorac Surg; 2010 Feb; 89(2):570-6. PubMed ID: 20103344
    [Abstract] [Full Text] [Related]

  • 67.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 68. Recombinant activated factor VII increases stroke in cardiac surgery: a meta-analysis.
    Ponschab M, Landoni G, Biondi-Zoccai G, Bignami E, Frati E, Nicolotti D, Monaco F, Pappalardo F, Zangrillo A.
    J Cardiothorac Vasc Anesth; 2011 Oct; 25(5):804-10. PubMed ID: 21596585
    [Abstract] [Full Text] [Related]

  • 69. Investigation of outcomes following recombinant activated FVII use for refractory bleeding during abdominal aortic aneurysm repair.
    Kandane-Rathnayake RK, Willis CD, Beiles CB, Bourke BM, Cameron PA, McCall P, Phillips LE.
    Eur J Vasc Endovasc Surg; 2013 Jun; 45(6):617-25. PubMed ID: 23433950
    [Abstract] [Full Text] [Related]

  • 70. Use of recombinant activated factor VII for controlling refractory postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass.
    Pychyńska-Pokorska M, Pągowska-Klimek I, Krajewski W, Moll JJ.
    J Cardiothorac Vasc Anesth; 2011 Dec; 25(6):987-94. PubMed ID: 21835642
    [Abstract] [Full Text] [Related]

  • 71.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 72.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 73.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 74. Recombinant activated factor VII for hemostasis in patients undergoing complex ascending aortic surgery: A single-center, single-surgeon retrospective analysis.
    Hang D, Koss K, Rokkas CK, Pagel PS.
    J Card Surg; 2021 Dec; 36(12):4558-4563. PubMed ID: 34608671
    [Abstract] [Full Text] [Related]

  • 75.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 76. Recombinant activated coagulation factor VII and bleeding trauma patients.
    Rizoli SB, Nascimento B, Osman F, Netto FS, Kiss A, Callum J, Brenneman FD, Tremblay L, Tien HC.
    J Trauma; 2006 Dec; 61(6):1419-25. PubMed ID: 17159685
    [Abstract] [Full Text] [Related]

  • 77.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 78. Cost-effectiveness of using recombinant activated factor VII as an off-label rescue treatment for critical bleeding requiring massive transfusion.
    Ho KM, Litton E.
    Transfusion; 2012 Aug; 52(8):1696-702. PubMed ID: 22211634
    [Abstract] [Full Text] [Related]

  • 79.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 80. Recombinant factor VIIa as last-resort treatment of desperate haemorrhage.
    Palmason R, Vidarsson B, Sigvaldason K, Ingimarsson JP, Gudbjartsson T, Sigurdsson GH, Onundarson PT.
    Acta Anaesthesiol Scand; 2012 May; 56(5):636-44. PubMed ID: 22489992
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.